HnRNP-L mediates bladder cancer progression by inhibiting apoptotic signaling and enhancing MAPK signaling pathways

Oncotarget. 2017 Feb 21;8(8):13586-13599. doi: 10.18632/oncotarget.14600.

Abstract

Heterogeneous nuclear ribonucleoprotein L (hnRNP-L) is a promoter of various kinds of cancers, but its actions in bladder cancer (BC) are unclear. In this study, we investigated the function and the underlying mechanism of hnRNP-L in bladder carcinogenesis. Our results demonstrated that enhanced hnRNP-L expression in BC tissues was associated with poor overall survival of BC patients. Depletion of hnRNP-L significantly suppressed cell proliferation in vitro and inhibited xenograft tumor growth in vivo. Furthermore, downregulation of hnRNP-L resulted in G1-phase cell cycle arrest and enhanced apoptosis accompanied by inhibition of EMT and cell migration. All these cellular changes were reversed by ectopic expression of hnRNP-L. Deletion of hnRNP-L resulted in decreased expression of Bcl-2, enhanced expression of caspases-3, -6 and -9 and inhibition of the MAPK signaling pathway. These findings demonstrate that hnRNP-L contributes to poor prognosis and tumor progression of BC by inhibiting the intrinsic apoptotic signaling and enhancing MAPK signaling pathways.

Keywords: MAPK; bladder cancer; epithelial-mesenchymal transition; heterogeneous nuclear ribonucleoprotein L; intrinsic apoptosis.

MeSH terms

  • Apoptosis / physiology
  • Cell Cycle Checkpoints
  • Cell Movement / physiology
  • Cell Proliferation / physiology
  • Disease Progression
  • Female
  • Heterogeneous-Nuclear Ribonucleoprotein L / genetics
  • Heterogeneous-Nuclear Ribonucleoprotein L / metabolism*
  • Humans
  • MAP Kinase Signaling System*
  • Male
  • Middle Aged
  • Signal Transduction
  • Up-Regulation
  • Urinary Bladder Neoplasms / enzymology
  • Urinary Bladder Neoplasms / genetics
  • Urinary Bladder Neoplasms / metabolism*
  • Urinary Bladder Neoplasms / pathology

Substances

  • Heterogeneous-Nuclear Ribonucleoprotein L